In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

British Biotech signs MMPI deal with Schering-Plough

Executive Summary

British Biotech and Schering-Plough will develop and market, as a cancer treatment, BB's matrix metalloproteinase inhibitors (MMPIs), including Marimastat and BB-3644. Schering gets exclusive worldwide rights except in Japan and those Far Eastern countries where Tanabe Seiyaku has rights.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register